CHM chimeric therapeutics limited

Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib, page-8

  1. 1,273 Posts.
    lightbulb Created with Sketch. 739
    This is a totally left field announcement, and shows how cutting edge the CORE NK platform is.

    This is initiator sponsored trial, setup by Jennifer Eva Selfridge at Case Comprehensive Cancer Center University Hospitals Cleveland.

    https://clinicaltrials.gov/ct2/show/NCT05400122

    Which means that Chimeric out of pocket costs might be only the CORE NK manufacturing.

    Fantastic update.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.3¢
Change
-0.001(25.0%)
Mkt cap ! $6.045M
Open High Low Value Volume
0.4¢ 0.4¢ 0.3¢ $22.28K 6.311M

Buyers (Bids)

No. Vol. Price($)
78 84735861 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 86304338 23
View Market Depth
Last trade - 14.27pm 25/07/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.